Liquidia's YUTREPIA Sales Climb 31% — But A Settlement Charge Pushes It Into Loss
Adjusted EBITDA rose for a fifth consecutive quarter, while Liquidia faces $380.7 million in net settlement payments.
Liquidia, which sells inhaled YUTREPIA for pulmonary arterial hypertension, recorded third-quarter product sales of $222.7 million, up 31% from the second quarter, according to its Tuesday earnings release accompanying an SEC filing. A $389.7 million litigation settlement charge pushed the company into a $236.3 million net loss.
Sales Growth Meets Settlement Costs
The loss amounted to $2.64 per share, compared with $3.5 million, or $0.04 per share, a year earlier. Adjusted EBITDA—a measure excluding the settlement, interest, taxes, depreciation and stock compensation—rose 46% from $96.3 million in the second quarter to $140.5 million, its fifth consecutive quarterly increase.
YUTREPIA sales compared with $51.7 million a year earlier, a gain Liquidia attributed to higher volume. Total revenue was $225.3 million versus $54.3 million, while paid patient demand for YUTREPIA was $212.2 million, excluding vouchers and patient access programs.
The October 13 settlement with United Therapeutics ended all six lawsuits and committed Liquidia to net payments of $380.7 million in installments during 2026 and 2027. Liquidia expects to fund those payments with existing cash and YUTREPIA sales. Cash stood at $396.1 million at September's end, before settlement payments, versus $190.7 million at the end of 2025.
The agreement followed a September 30 ruling by the U.S. District Court for the District of Delaware that certain patent claims covering treatment of pulmonary hypertension associated with interstitial lung disease were valid and infringed. Liquidia agreed not to appeal, submitted an application to remove that use from YUTREPIA's label and stopped promoting it. Patients can continue treatment without interruption.
More Prescribers, Higher Commercial Costs
Liquidia launched YUTREPIA in June 2025 after FDA approval in May 2025. The drug delivers treprostinil through a dry-powder inhaler; Liquidia's U.S. sales force calls on healthcare providers treating pulmonary hypertension.
October patient shipments reached their highest monthly level since launch. The prescriber base reached 1,300 through October, with more first-time prescribers added than in September, and more than 87% of monthly referrals converted into treatment starts.
More than 60% of referrals from launch through September included a pulmonary arterial hypertension diagnosis, rising above 70% in September. Roughly 60% of prescribers had written prescriptions for two or more patients, more than 30% for at least five, and 77% had prescribed for pulmonary arterial hypertension since launch.
Selling and administrative spending rose 47% to $59.0 million from $40.1 million a year earlier. Liquidia primarily attributed that increase to personnel, stock compensation and commercialization costs. Product sales costs reached $14.0 million versus $2.3 million, which the company primarily tied to higher sales volume.
Liquidia ended its Sandoz promotion agreement in October and will no longer earn service revenue from sharing U.S. treprostinil injection profits. That business contributed $2.6 million in third-quarter revenue, compared with $2.7 million a year earlier.
Trial Spending And 2027 Milestones
Research spending rose to $25.3 million from $9.3 million a year earlier. Liquidia primarily attributed the increase to its L606 program, YUTREPIA studies and additional staff; L606 alone accounted for $11.1 million of the increase.
Liquidia Chief Executive Officer Roger Jeffs said, "we will continue to advance a pipeline that builds on our deep understanding of inhaled treprostinil," including uses for which patients have no approved options.
Liquidia enrolled the first patient in its YUTREPIA dose-finding trial for systemic sclerosis-associated Raynaud's attacks and anticipates primary completion in the first quarter of 2027. The program received FDA Fast Track designation in September; YUTREPIA is not approved for that use. Its study of patients switching from oral selexipag is underway, with primary completion anticipated in the second quarter of 2027.
L606, an experimental extended-release treprostinil treatment delivered twice daily through a nebulizer, is enrolling patients in a study for pulmonary hypertension associated with interstitial lung disease. Liquidia anticipates finishing enrollment in 2028 and primary completion in 2029. It also anticipates starting enrollment in a pulmonary arterial hypertension study in 2027, with primary completion in 2029, and beginning a study for pulmonary hypertension associated with chronic obstructive pulmonary disease in the second half of 2027.
The settlement protects YUTREPIA's availability for pulmonary arterial hypertension, but does not cover other indications or new treprostinil-containing products. Liquidia warned that United Therapeutics may assert patents against its development programs or future products.
Sources
- 8-K Filing — Liquidia Corp (LQDA) — SEC EDGAR
- Exhibit tm2629427d1_ex99-1.htm — Liquidia Corp 8-K exhibit — SEC EDGAR
- Exhibit tm2629427d1_ex99-2.htm — Liquidia Corp 8-K exhibit — SEC EDGAR
- Liquidia GAAP EPS of -$2.64 misses by $3.60, revenue of $225.3M beats by $11.15M (LQDA:NASDAQ) | Seeking Alpha — seekingalpha.com
- Liquidia Corporation Reports Third Quarter 2026 Financial — globenewswire.com
- 8-K filed 2026-10-14 — Liquidia Corp (earlier disclosure) — SEC EDGAR